)
JD Health International (6618) investor relations material
JD Health International H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
H1 2026 revenue rose 15.9% YoY to RMB40.9bn, driven by growth in product and service revenue.
Non-IFRS operating income increased 40.3% to RMB3.5bn; non-IFRS operating margin reached 8.5%, improving for a ninth consecutive quarter.
Reported operating income rose 49.2% to RMB3.2bn and profit for the period increased 32.6% to RMB3.4bn.
Strategic priorities included user experience, AI-powered healthcare services and supply chain integration.
Financial highlights
Product revenue grew 15.6% to RMB33.9bn; service revenue rose 17.2% to RMB7.0bn.
Gross profit increased 20.2% to RMB10.7bn; gross margin improved to 26.1% from 25.2%.
Fulfillment expenses rose 15.0% to RMB4.1bn, while the ratio to revenue declined to 10.0%.
Selling and marketing expenses increased 3.7% to RMB1.9bn, with the ratio to revenue falling to 4.6%; R&D expenses rose 23.5% to RMB909.1m.
Basic EPS was RMB1.08, up from RMB0.82 YoY.
Outlook and guidance
H2 growth is expected to exceed the industry, with continued strengthening in online pharmacy retail.
H2 nutrition and supplements growth is expected to slow from H1, though management anticipates improvement; medical equipment has a positive long-term outlook.
The long-term operating margin target remains high single digits, supported by scale, supply chain improvements, AI services and operating efficiency.
Scaling healthcare services and balancing high-frequency, lower-margin products with lower-frequency, higher-margin business could support gross margin improvement.
- Record revenue and profit growth driven by AI healthcare, new drugs, and omnichannel expansion.6618
H2 2025 - Revenue and profit surged, driven by AI innovation and omnichannel healthcare expansion.6618
H1 2025 - Net profit jumped 30.2% on 4.6% revenue growth, led by digital health and strong cash position.6618
H1 2024 - Net profit nearly doubled in 2024 as digital and AI healthcare services expanded.6618
H2 2024
Next JD Health International earnings date
Next JD Health International earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)